Latest Breaking News On - Jort vijverberg - Page 1 : comparemela.com

Cognition Therapeutics Releases New Episode Of Conversations Podcast: Protecting The Synapse From Amyloid Toxicity In Alzheimer s Disease

PURCHASE, N.Y., May 21, 2024 (GLOBE NEWSWIRE)

Jort vijverbergMary hambyAnthony caggianoAmsterdam alzheimer center at neuroscienceCompany or cognitionCognition therapeutics incHealth care disclaimerAmyloid toxicityCognition therapeuticsStaff neurologistAmsterdam alzheimer centerAmsterdam neuroscienceSpires jonesPersonal chairDeputy directorDiscovery brain sciences

Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer s disease

PURCHASE - Cognition Therapeutics, Inc., , a clinical stage company developing drugs that treat neurodegenerative disorders, provided a recap of the virtual KOL event hosted on April 12, 2024.

Noord hollandAnton porsteinssonJort vijverbergMike moyerCasey mcdonaldMartinj sadowskiLisa ricciardiCompany or cognitionSecurities exchange commissionCognition therapeutics incAlzheimer center amsterdamUniversity of rochester alzheimer disease careSchool of medicineEducation programRochester alzheimerDisease care

Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer s Disease on April 12, 2024 -April 01, 2024 at 07:31 am EDT

NEW YORK, April 01, 2024 Cognition Therapeutics, Inc. , a clinical stage company developing drugs that treat neurodegenerative disorders, today announced it will host a virtual KOL event on.

United statesNoord hollandCasey mcdonaldAnton porsteinssonMartinj sadowskiMike moyerJort vijverbergHenrym wisniewskiResearch in drUniversity of amsterdamYork university school of medicineAlzheimer associationAmerican federation for aging researchSchool of medicineCompany or cognitionCognition therapeutics inc

Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer s Disease at CTAD

PURCHASE, N.Y., Oct. 24, 2023 (GLOBE NEWSWIRE) Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) announced that Willem de Haan, M.D., Ph.D., a neurologist and senior researcher at the Amsterdam University Medical Centers’ Alzheimer Center, is presenting complete EEG findings from the Phase 2 SEQUEL study at the Clinical Trials on Alzheimer’s Disease (CTAD) conference. SEQUEL was conducted at the Amsterdam UMC in the Netherlands with Everard (Jort) Vijverberg, M.D.,

Noord hollandCasey mcdonaldJort vijverbergDaniel kontoh boatengCognition therapeutics incCompany or cognitionTiberend strategic advisors incNational institutes of healthNational institute of agingSecurities exchange commissionAmsterdam university medical center alzheimerWillem de haanClinical trialsCognition therapeuticsNational instituteNational institutes

Cognition Therapeutics (CGTX) Reports Positive Topline Results for CT1812 Phase 2 SEQUEL Study

Cognition Therapeutics (CGTX) Reports Positive Topline Results for CT1812 Phase 2 SEQUEL Study
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Noord hollandLisa ricciardiAnthony caggianoDaniel kontoh boatengJort vijverbergAline sherwoodSecurities exchange commissionAmsterdam university medical center alzheimerScienta communicationsTiberend strategic advisors incCognition therapeutics incNational institute on agingAmsterdam university medical centersCognition therapeuticsWillem de haanNational institute